Bayer scores late-stage support for new PAH drug

Just days after nabbing a speedy FDA approval of its cancer drug Stivarga (regorafenib), Bayer says it nailed positive Phase III data on its new drug for rare cases of pulmonary arterial hypertension--and that could set the stage for a three-way market-share battle with Actelion ($ATLN) and Gilead ($GILD) in 2014. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.